Phagenesis appoints Chairman and CEO
Phagenesis Limited has appointed Henry Hyde-Thomson as Chairman and Daniel Green as Chief Executive Officer. They will lead Phagenesis in the development of a new class of treatments for stroke victims suffering from dysphagia, a common condition that prevents or impairs the safe swallowing of food and drink.
Daniel Green, formerly CEO of Repregen Ltd, said: “Phagenesis has a technology that had already shown its value in patients for whom there is no effective pharmaceutical or medical device treatment. Our challenge is to bring this technology to the benefit of patients and health services everywhere.” Daniel co-founded Repregen as an Imperial College spinout in 2006. Before that, was a venture capital investor at HBM Partners in Zurich, Switzerland, Dresdner Kleinwort, in London, UK, and MVM, also London, UK.
Henry Hyde-Thomson, Chairman of AngloScientific said: “This is an exciting time for Phagenesis as the company commercialises the results of 15 years development by the company’s scientific founder, Dr Shaheen Hamdy.” Henry is chairman of 21Net, Phasor Solutions and MMIC Solutions, and was previously founder and chairman of Speech Machines, acquired by Philips in 2001.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
